The vertex predicts 2025 revenues for demand for cystic fibrosis treatment 2025
(Reuters) – The top drug forecasts annual revenues that are largely above Wall Street estimates on Monday, with robust sales of cystic fibrosis drugs and early contributions from newly approved non-opioid painkillers I’m banking a bank.
Drugmakers are looking for its acute pain medication, Journavx, to promote growth beyond the established lineage of cystic fibrosis treatment. Vertex plans to begin shipping Journavx to US pharmacies by the end of February.
The US Food and Drug Administration approved Alyftrek, apex-day next-generation treatment, for rare and progressive genetic diseases, in December, bringing the market advantage in cystic fibrosis (CF) treatment. It has been expanded.
CF is a hereditary disorder caused by the lack of certain proteins, where the flow of salt and water in and out of cells in various organs is insufficient.
In the fourth quarter, which ended December 31st, sales of the company’s old CF treatment Trikafta rose nearly 17% to $2.72 billion.
The company aims to launch five new therapies by 2028. This includes next-generation CF drugs and non-opioid pain control drugs.
In December, Vertex signed an agreement with the Centers for Medicare and Medicaid Services to help increase patient access to its gene therapy. Casgevy treats rare blood disorders that require regular blood transfusions.
The Boston, Massachusetts-based drugmaker developed Casgevy along with Swiss-American CRISPR Therapeutics.
Vertex, according to data compiled by LSEG, revenues in 2025 ranged from $11.75 billion to $12 billion, with a midpoint exceeding the average analyst forecast of $11.84 billion.
The company’s fourth quarter revenue rose nearly 16% to $29.1 billion, with analysts’ estimates of $2.78 billion.
On an adjusted basis, the company reported earnings of $3.98 per share for the quarter compared to analysts’ forecasts for earnings of $4.03 per share.
(Reporting by Sriparna Roy and Christy Santhosh of Bengaluru, edited by Mohammed Safi Shamsi)